In a model representing the lack of response to immune checkpoint inhibitors (ICI) in non-alcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC), the combined administration of a CXCR2 antagonist and anti-PD1 has demonstrated efficacy in reducing tumor burden and extending survival. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.